ISIS Pharmaceuticals, Inc. Stock price Nasdaq
Equities
US4643301090
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 635M | Sales 2025 * | 764M | Capitalization | 6.13B |
---|---|---|---|---|---|
Net income 2024 * | -583M | Net income 2025 * | -523M | EV / Sales 2024 * | 9.29 x |
Net cash position 2024 * | 226M | Net Debt 2025 * | 170M | EV / Sales 2025 * | 8.24 x |
P/E ratio 2024 * |
-10.4
x | P/E ratio 2025 * |
-11.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.69% |
Latest transcript on ISIS Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 12-06-30 |
Brett Monia
FOU | Founder | 62 | 89-01-09 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 00-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 14-02-02 |
Brett Monia
FOU | Founder | 62 | 89-01-09 |
Joan Herman
BRD | Director/Board Member | 70 | 19-06-09 |
1st Jan change | Capi. | |
---|---|---|
+9.72% | 46.21B | |
+34.35% | 40.04B | |
+4.84% | 39.92B | |
-9.43% | 28.33B | |
+17.47% | 27.43B | |
-22.99% | 18.57B | |
+10.88% | 13.46B | |
+27.53% | 12.02B | |
-6.84% | 11.3B |